Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/72894
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNgo, D.en
dc.contributor.authorSverdlov, A.en
dc.contributor.authorHorowitz, J.en
dc.date.issued2012en
dc.identifier.citationPharmacology & Therapeutics, 2012; 135(1):78-93en
dc.identifier.issn0163-7258en
dc.identifier.issn1879-016Xen
dc.identifier.urihttp://hdl.handle.net/2440/72894-
dc.description.abstractAortic valve stenosis (AS) is the most common form of valvular heart disease in the Western world, affecting ~40% of the population over the age of 80; to date the only established treatment is valve replacement. However, AS progression occurs over many years, and is associated from its earliest stages with increased risk of coronary events. Recent insight into the pathophysiology of AS has included central roles for angiotensin II, for diminished nitric oxide effect at the level of valve endothelium and matrix, and for inflammatory activation/redox stress culminating in activation of pro-calcific stimuli. Despite the presence of atheroma within the stenotic valve, hyperlipidemia per se does not play a critic role in the development of obstructive disease. We review emerging options for pharmacotherapy of AS, including in particular retardation of disease progression. The various clinical evaluations of lipid-reducing therapy have been uniformly unsuccessful in slowing AS progression. However, recent studies in animal models and retrospective evaluations in humans suggest that ACE inhibitors and/or angiotensin receptor blockers may be effective in this regard. Furthermore, agents normally utilized to treat osteoporosis also offer promise in retarding AS. Given the considerable morbidity, mortality and health care costs associated with AS, such therapeutic developments should be expedited.en
dc.description.statementofresponsibilityD.T. Ngo, A.L. Sverdlov and J.D. Horowitzen
dc.language.isoenen
dc.publisherPergamon-Elsevier Science Ltden
dc.rights© 2012 Elsevier Inc. All rights reserved.en
dc.subjectAortic Valve; Animals; Humans; Aortic Valve Stenosis; Disease Progression; Nitric Oxide; Guanylate Cyclase; Receptors, Cytoplasmic and Nuclear; Cardiovascular Agents; Risk Assessment; Risk Factors; Oxidation-Reduction; Oxidative Stress; Renin-Angiotensin System; Soluble Guanylyl Cyclaseen
dc.titlePrevention of aortic valve stenosis: a realistic therapeutic target?en
dc.typeJournal articleen
dc.identifier.doi10.1016/j.pharmthera.2012.04.001en
pubs.publication-statusPublisheden
dc.identifier.orcidSverdlov, A. [0000-0003-2539-8038]en
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.